Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220811 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
A Phase 2 study of Ig-E Mediated Food Allergy, sponsored by RAPT Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 15
- Study locations
NCT07220811 is a Phase 2 study of Ig-E Mediated Food Allergy that is actively recruiting participants, run by RAPT Therapeutics. The registered enrollment target is 100 participants. The trial reports 15 study locations across 13 states.
The verdict
NCT07220811, a Phase 2 study of Ig-E Mediated Food Allergy, is actively recruiting participants, sponsored by RAPT Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 15
- Study locations
Study Summary
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generation anti-IgE monoclonal antibody, in people with food allergy. RPT904 is a long-acting antibody that may allow for dosing every 8 to 12 weeks. Approximately 100 participants between the ages of 12 and 55 with documented allergy to at least one of the following foods: peanut, milk, egg, cashew, or walnut will be enrolled. In Part 1 (24 weeks), participants will be randomly assigned to receive RPT904 every 8 or 12 weeks (plus a loading dose at Week 2), or placebo. In Part 2 (24 weeks), participants who received RPT904 will continue on their assigned dosing schedule, and those who previously received placebo will be re-randomized to receive RPT904 either every 8 or 12 weeks (plus a loading dose at Week 26). All participants will attend study visits approximately every 2-6 weeks throughout both Part 1 and Part 2 to maintain blinding, regardless of treatment group or dosing frequency. The study is being conducted at multiple sites. The primary goal is to assess whether RPT904 helps participants tolerate higher amounts of a food allergen without dose-limiting allergic symptoms during a food challenge. The study will also monitor the safety and side effects of RPT904 over time. Each participant is expected to be in the study for about 68 to 74 weeks, including screening, treatment, and follow-up.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG RPT904
Study Locations (15)
New South Wales
- St Vincent's Hospital Sydney - Darlinghurst
- Children's Hospital at Westmead - Westmead
Ontario
- Halton Pediatric Allergy - Burlington
- Ottawa Allergy Research Corporation - Ottawa
Arkansas
- Arkansas Children's - Little Rock
California
- Sean N. Parker Center for Allergy and Asthma Research - Palo Alto
Colorado
- Asthma & Allergy Associates, P.C. - Colorado Springs
District of Columbia
- Children's National Hospital - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics - Atlanta
Massachusetts
- Boston's Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220811
The ClinicalTrials.gov registry entry for NCT07220811 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RAPT Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ig-E Mediated Food Allergy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07220811 reports 15 study locations spanning 13 distinct geographic areas - top geographies include New South Wales, Ontario, Arkansas.
Frequently Asked Questions
What is clinical trial NCT07220811 about?
NCT07220811 is a clinical study titled "Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy". Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generation anti-IgE monoclonal antibody, in people with food allergy. RPT904 is a long-acting antibody that...
What is the current status of trial NCT07220811?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-10-22. Estimated completion is 2028-01.
What conditions does trial NCT07220811 study?
This clinical trial studies the following conditions: Ig-E Mediated Food Allergy.
What interventions are being tested in trial NCT07220811?
The interventions under investigation include: Placebo (OTHER), RPT904 (DRUG).
Who is sponsoring clinical trial NCT07220811?
This trial is sponsored by RAPT Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220811 being conducted?
This trial has 15 study locations across Arkansas, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.